<![CDATA[V940 Plus Pembrolizumab Cuts Melanoma Recurrence Risk by 49%]]>

Data ReadoutpositiveV940pembrolizumabPositive

AI Analysis

Summary

V940 in combination with pembrolizumab demonstrated efficacy in resected melanoma, reducing recurrence risk by 49%. Data presented by Dr. Matteo S. Carlino showing positive results for the combination therapy approach.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

V940 plus pembrolizumab reduced melanoma recurrence risk by 49%

Importance:6/10

Sentiment:

0.80

melanomaoncologycombination therapyrecurrence reduction

Related Companies

$MRK

Read the original article

Published by Cancer Network on August 31, 2026 2:00 PM

Read Original